These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16434386)

  • 1. The role of second autografts in the management of myeloma at first relapse.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Morgan GJ
    Haematologica; 2006 Jan; 91(1):141-2. PubMed ID: 16434386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
    Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
    Tricot G; Jagannath S; Vesole DH; Crowley J; Barlogie B
    Bone Marrow Transplant; 1995 Jul; 16(1):7-11. PubMed ID: 7581132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
    Lenhoff S; Hjorth M; Turesson I; Westin J; Gimsing P; Wislöff F; Ahlberg L; Carlson K; Christiansen I; Dahl IM; Forsberg K; Brinch L; Hammerström J; Johnsen HE; Knudsen LM; Linder O; Mellqvist UH; Nesthus I; Nielsen JL;
    Haematologica; 2006 Sep; 91(9):1228-33. PubMed ID: 16956822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
    Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F
    Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.
    Tauro S; Clark FJ; Duncan N; Lipkin G; Richards N; Mahendra P
    Bone Marrow Transplant; 2002 Oct; 30(7):471-3. PubMed ID: 12368962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem bone marrow transplantation in multiple myeloma.
    Chng WJ
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
    [No Abstract]   [Full Text] [Related]  

  • 11. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of autologous hematopoietic stem cell transplantation in myeloma.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
    Wiesmann A; Einsele H; Kanz L; Dohmen BM
    Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years.
    Corso A; Mangiacavalli S; Barbarano L; Alessandrino EP; Cairoli R; Morra E; Lazzarino M;
    Cancer; 2007 Jun; 109(11):2273-8. PubMed ID: 17440982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.